Revenue, 2025

USD 21.85 Billion

Forecast, 2035

USD 55.65 Billion

CAGR, 2026-2035

9.8%

Report Coverage

Global

Biologics Contract Manufacturing Market Trends for 2026

The global biologics contract manufacturing market size was estimated at USD 21.85 billion in 2025 and is predicted to increase from USD 23.99 billion in 2026 to approximately USD 55.65 billion by 2035, expanding at a CAGR of 9.8% from 2026 to 2035. The biologics contract manufacturing market is increasing due to the prevalence of chronic diseases like diabetes, cancer, and autoimmune disorders, which is increasing the demand for biologics, leading medicinal companies to increase outsourcing to contract manufacturers for large-scale manufacturing.

Key Takeaways

• The biologics contract manufacturing market will likely exceed USD 23.99 billion by 2026.
• Valuation is projected to hit USD 55.65 billion by 2035.
• Estimated to grow at a CAGR of 9.8% starting from 2026 to 2035.
• North America dominated the biologics contract manufacturing market with a share of 38% in 2025.
• Asia Pacific held 24% share of the market, expected to grow at the fastest rate of 11.8% CAGR during the forecast period.
• By product type, the monoclonal antibodies (mAbs) segment held 42% market share in 2025.
• By product type, the cell & gene therapy products segment held the market share of 12% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By source, the mammalian cells segment held the largest market share of 64% in 2025.
• By source, the insect cells segment held a significant market share of 8% in 2025, and is expected to grow at the fastest CAGR of 10.2% during the forecast period.
• By service type, the upstream processing segment held the largest market share of 30% in 2025.
• By service type, the fill-finish operations segment held a notable market share of 18% in 2025 and is expected to grow at the fastest rate of 10.8% CAGR during the forecast period.
• By end user, the pharmaceutical companies segment held the largest biologics contract manufacturing market share of 48% in 2025.
• By end user, the biotechnology companies segment held a notable market share of 23% in 2025 and is expected to grow at the fastest rate of 11.5% CAGR during the forecast period.

Market Overview: What is Biologics Contract Manufacturing?

Biologics contract manufacturing services quicken the development of biopharmaceuticals from concept to cure. It provides biologics contract manufacturing, including cell line advancement (MCB/WCB) and large molecule production. Biologics CDMO is an outside partner that provides comprehensive solutions in the development and manufacturing of biologic medicine. These solutions encompass everything from initial advancement to commercial productions, including government support, analytical testing, and packaging.

How is AI governing the Biologics Contract Manufacturing Market?

AI-powered predictive analytics are transforming the assessment of biologic drug stability. By forecasting the shelf life and stability of biologics, AI boosts supply chain efficiency and helps products retain their effectiveness throughout their lifecycle. Artificial intelligence is also revolutionizing how biopharma companies evaluate CDMOs, especially in the complex areas of biologics and CGT. AI algorithms are streamlining bioprocessing workflows, shortening production timelines, and improving yield predictability. Additionally, AI enhances the shift from laboratory to commercial scale by predicting yields and optimizing fermentation and purification protocols. Furthermore, AI and Machine Learning (ML) tools are advancing biologics discovery, moving toward the de novo design of new biological entities drug.

Future Outlook Trends in the Biologics Contract Manufacturing Market

• Continuous Bioprocessing: Continuous bioprocessing shift in biopharma is driven by demand for effectiveness, higher yields, and superior quality control, renovating the industry. Use of continuous bioprocessing is likely to further drive with the arrival of more hybrid systems that use bolt-on-type technology, which retrofit components to unit operations for presenting systems.
• Single-Use Technologies (SUTs): Single-use systems transformed bioprocessing by offering contamination control, expense savings, simplified validation, rapid turnaround times, and sustainability advantages. As the biopharmaceutical sector continues to advance, single-use systems remain a significant enabler of flexible and efficient biopharmaceutical manufacturing.
• Next-Gen Antibodies: Next-generation antibodies are intended to be more specific and are often more potent than traditional monoclonal antibodies (mAbs). This antibody format involves ADCs, other bioconjugates, bispecific antibodies, nanobodies, engineered antibodies, antibody fragments, and antibody-based proteins.

Executive Summary Table

Segmentation Analysis

By Product Type Insights

The Monoclonal Antibodies (mAbs) Segment Led the Biologics Contract Manufacturing Market in 2025

The monoclonal antibodies (mAbs) segment contributed the largest market share of 42% in 2025, as monoclonal antibodies are manufactured proteins intended to function such as human antibodies in the immune system. Monoclonal antibodies are one of the most effective reagents for a broad range of applications. mAbs are engineered proteins intended to bind with high specificity to molecules that cause diseases, allowing targeted modulation of biological pathways.

The recombinant proteins segment held a significant share of 18% in the market, as recombinant proteins have overcome restraints in sourcing from natural organisms, making them broadly accessible to scientists and pharmaceutical organizations. Recombinant proteins remove the challenges of contamination from pathogens that are present in natural sources.

The vaccines segment held a significant share of 14% in the market, as vaccine production in biologics contract manufacturing provides significant benefits, involving accelerated time, access to specialized expertise in new platforms such as mRNA and viral vectors, and enhanced regulatory compliance.

The cell & gene therapy products segment held a significant share of 12% in the market, and is expected to grow at the fastest CAGR during the forecast period, as cell and gene technologies offer effectiveness and flexibility while lowering challenges in the production of cell and gene therapies. Cell and gene therapy CDMOs work as a specialised extension of a biopharma’s team, providing their knowledge, services, and tools to handle significant parts of C> advancement and manufacturing.

By Source Insights

Mammalian Cells Segment Led the Biologics Contract Manufacturing Market in 2025

The mammalian cells segment contributed the largest market share of 64% in 2025. Mammalian cell culture provides advantages like the capability to research complex cellular functions and mimic human physiological conditions.  Mammalian cells produce numerous glycoform patterns, which are affected by culture conditions.

The microbial cells segment held a significant share of 22% of the market, as microbial cells have been used for decades to produce biologics, involving insulin and other recombinant proteins. It provides a clear operational benefit to substitutes such as mammalian cell culture.

The insect cells segment held a significant share of 8% of the market, as expected to grow at the fastest rate of 10.2% during the forecast period. Insect cell culture creates high levels of recombinant proteins and can be simply adapted to high-density suspension culture. It provides advantages for expressing intracellular proteins and multi-protein complexes that are difficult to obtain using mammalian and bacterial systems.

The plant-based systems segment held a significant share of 6% of the market, as increasing applications of plants in vaccine production provide various advantages, involving rapid scalability, low cost, and the capability to produce vaccines without the requirement for refrigeration.

By Service Type Insight

Upstream Processing Segment Led the Biologics Contract Manufacturing Market in 2025

The upstream processing segment contributed the largest market share of 30% in 2025, as the upstream processing stage of biologics manufacturing includes the cultivation of cells in bioreactors to produce the intended product. Upstream processing goal to optimize the microbial or cell culture's development and productivity while ensuring purity and quality.

The downstream processing segment held a significant share of 25% in the market, as this bioprocessing is responsible for separating the particular protein from complex cell culture harvests while ensuring product safety, purity, and quality. Its effectiveness is influenced by the recombinant protein concentration, the difficulty of the plant extracts or cell-free ethos.

The fill-finish operations segment held a significant share of 18% in the market, and is expected to grow at the fastest CAGR of 10.8% during the forecast period, as contract fill finish manufacturing processes to fill finish manufacturing organization provides a cost saving strenth for drug developers as it lowers the capital expenditure related to the establishment of well-equipped filling lines.

The analytical & QC services segment held a significant share of 15% in the market, as CDMOs with advanced analytical development and testing abilities brilliantly supplement or even support to strengthen production capabilities. Analytical testing and processes support bio/pharmaceutical organizations in expanding their product profiles.

By End User Insights

Pharmaceutical Companies Segment Led the Biologics Contract Manufacturing Market in 2025

The pharmaceutical companies segment contributed the largest market share of 48%, as these biopharmaceutical companies provide many distinct benefits over small molecules, making them a popular choice among patients, healthcare teams, and drug makers alike. It avoids significant capital spending to build R&D and clinical manufacturing services.

The biotechnology companies segment held a significant share of 32% in the market, and is expected to grow at the fastest rate of 11.5% during the forecast period, as biotechnology is significantly reshaping the medical care business, allowing the advancement of well-developed therapies, enhancing patient results. Biotechnology has supported the pharma industry in the development of better technology and novel products.

The research institutes segment held a significant share of 10% in the market, as these institutes offer access to highly skilled experts, dedicated knowledge in molecular biology, and advanced technologies such as single-use systems. Outsourcing removes substantial capital spending on infrastructure and equipment.

The contract research organizations (CROs) centers segment held a significant share of 10% in the market, as biologics contract development and manufacturing organization (CDMO) offers biological medical product advancement and production services for pharmaceutical organizations.

Regional Insight

Why North America Dominated the Market in 2025?

In 2025, North America dominated the biologics contract manufacturing market with a share of 38% in 2025, due to advance biotechnology network, extensive spending in research and development, and a strong government framework that supports novelty. The presence of various biopharmaceutical organizations, combined with academic institutions and research facilities. accepting advanced technologies, like single-use bioreactors, incessant processing, and AI-based automation, drives the growth of the market.

For Instance,

• In March 2026, Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced the completion of its acquisition of a production facility in Rockville, Maryland, from GSK, establishing the company’s first manufacturing presence in the United States.

U.S. Market Trends

In the U.S., three in four adults have at least one long-term condition, and over half have two or more chronic conditions. The U.S. is a worldwide powerhouse in healthcare contract development and manufacturing, a hub to some of the world's most well-developed CDMOs. Biopharma and biotech organizations rely on CDMOs to cover internal capacity, achieve scale, and execute challenging manufacturing approaches.

Asia Pacific: Advancement in Technology

Asia Pacific held 24% share of the biologics contract manufacturing market, and is expected to have the fastest CAGR of 11.8% during the forecast period, due to healthcare technology in the Asia-Pacific region being confronted with vast complexities because of an aging population and its increasing demand for healthcare services.  Technological development, socioeconomic conditions, and the government landscape eventually revolutionise medical care delivery in APAC, which contributes to the growth of the market.

India Market Trends

In India, a growing aging population and an increasing prevalence of chronic diseases such as cancer and diabetes in APAC are driving massive internal demand for biologic therapies. India is transitioning from generics dominance to a worldwide biologic and biosimilars leader, shaping the future of well-developed therapies. India has a significant pharma network, with more than 10,000 manufacturing services and over 3,000 pharma organizations.

Supply Chain Analysis

R&D:

• Research and development (R&D) in biologics contract manufacturing involves cell line development, optimization of upstream and downstream processes, analytical processes advancement for characterization, and formulation research to ensure stability.
• Key Players: Lonza Group Ltd and Samsung Biologics

Manufacturing Processes:

• Biologics contract manufacturing involves complex upstream cell culture, such as fermentation, bioreactors, and downstream purification, like chromatography and filtration, to produce drug substances under cGMP.
• Key Players: WuXi Biologics and FUJIFILM Diosynth Biotechnologies

Patient Services:

• Patient services related to biologics contract manufacturing ensure the efficacy, safety, quality, and timely delivery of complex, life-saving therapies such as monoclonal antibodies, cell therapies, and vaccines to patients.
• Key Players: Boehringer Ingelheim and Catalent, Inc.

Latest Updates of Key Players in the Biologics Contract Manufacturing Market

SWOT Analysis

Strengths

• Biologics contract manufacturing processes enable pharmaceutical companies to access dedicated facilities, lower expenses, and accelerate development timelines.
• Contract manufacturing enables pharmaceutical organizations to focus their resources on research and advancement, while leaving the manufacturing process to experienced third-party manufacturers.

Weakness

• Biologics manufacturing needs highly specialised knowledge, tools, and facilities, which can be complex for a pharmaceutical organization to maintain in-house.

Opportunities

• The biologics production industry has undergone a significant revolution in recent decades, with continuous development in technology and methodology driving more effective biologics production technology.
• Single-use bioreactors (SUBs) have develop significant in bioprocessing, offering lowered contamination challenges and efficient biomolecule synthesis.

Threat

• Biologics are produced using living cells such as mammalian and microbial cells, which are sensitive to environmental fluctuations like pH and temperature, causing to high variability in quality and yield.

Recent Developments in the Biologics Contract Manufacturing Market

• In April 2026, WuXi Biologics completed the structure of a novel microbial scalable production site in Chengdu and received significant tool shipments, as the contract development and manufacturing organization works toward good manufacturing practices.
• In April 2026, Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75bn. The move is set to significantly expand the company's global pharmaceutical manufacturing footprint and strengthen its presence in women's health

Segments Covered in the Report

By Product Type

• Monoclonal Antibodies (mAbs)
  • Naked Antibodies
  • Conjugated Antibodies
• Recombinant Proteins
  • Hormones
  • Growth Factors
  • Fusion Proteins
• Vaccines
  • Viral Vaccines
  • Bacterial Vaccines
• Cell & Gene Therapy Products
  • Cell Therapy
  • Gene Therapy
• Biosimilars
• Others

By Source

• Mammalian Cells
  • CHO Cells
  • HEK293 Cells
  • BHK Cells
• Microbial Cells
  • Bacteria (E. coli)
  • Yeast
• Insect Cells
• Plant-based Systems

By Service Insight

• Upstream Processes
  • Cell Line Development
  • Cell Culture
• Downstream Processes
  • Purification
  • Filtration
• Fill-Finish Operations
• Analytical & QC Services
• Packaging & Labeling

By Scale of Operation

• Preclinical
• Clinical
  • Phase I
  • Phase II
  • Phase III
• Commercial Manufacturing

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Contract Research Organizations (CROs)

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA